Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

1.

Post-licensing safety of fosamprenavir in HIV-infected children in Europe.

Judd A, Duong T, Galli L, Goetghebuer T, Ene L, Julian AN, Ramos Amador JT, Pimenta JM, Thorne C, Giaquinto C; European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord.

Pharmacoepidemiol Drug Saf. 2014 Mar;23(3):321-5.

PMID:
24741696
[PubMed - in process]
Free PMC Article
2.

Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.

Gathe JC Jr, Wood R, Sanne I, DeJesus E, Schürmann D, Gladysz A, Garris C, Givens N, Elston R, Yeo J.

Clin Ther. 2006 May;28(5):745-54.

PMID:
16861096
[PubMed - indexed for MEDLINE]
3.

Long-term safety study of fosamprenavir-containing regimens in HIV-1-infected patients.

Wood R, Gathe JC, Givens N, Sedani S, Cheng K, Sievers J.

HIV Clin Trials. 2013 Sep-Oct;14(5):183-91. doi: 10.1310/hct1405-183.

PMID:
24144895
[PubMed - indexed for MEDLINE]
4.

Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.

Molina JM, Ait-Khaled M, Rinaldi R, Penco G, Baril JG, Cauda R, Soriano V, Pialoux G, Wire MB, Lou Y, Givens N, Craig C, Nichols WG, Barbosa I, Yeo J; TRIAD Study Group.

J Antimicrob Chemother. 2009 Aug;64(2):398-410. doi: 10.1093/jac/dkp198. Epub 2009 Jun 10.

PMID:
19515730
[PubMed - indexed for MEDLINE]
Free Article
5.

Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks.

Pulido F, Estrada V, Baril JG, Logue K, Schewe K, Plettenberg A, Duiculescu D, Yau L, Vavro C, Lim ML, Pharo C.

HIV Clin Trials. 2009 Mar-Apr;10(2):76-87. doi: 10.1310/hct1002-76.

PMID:
19487177
[PubMed - indexed for MEDLINE]
6.

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.

Gathe JC Jr, Ive P, Wood R, Schürmann D, Bellos NC, DeJesus E, Gladysz A, Garris C, Yeo J.

AIDS. 2004 Jul 23;18(11):1529-37.

PMID:
15238771
[PubMed - indexed for MEDLINE]
7.

Long-term efficacy and safety of once-daily fosamprenavir 1400 mg boosted by ritonavir 100 mg: the BOLD100 study.

Blick G, Greiger-Zanlungo P, Gretz S, Han J, Dupree D, Garton T, Yau LH, Wine BC, Pakes GE; Boosting Once-daily Lexiva Delivery with ritonavir 100 mg QD [BOLD100] Study Team.

Int J STD AIDS. 2012 Mar;23(3):e18-22. doi: 10.1258/ijsa.2009.009161.

PMID:
22581890
[PubMed - indexed for MEDLINE]
8.

Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients.

Gyalrong-Steur M, Bogner JR, Seybold U.

Eur J Med Res. 2011 Feb 24;16(2):85-92.

PMID:
21463988
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients.

Merchante N, López-Cortés LF, Delgado-Fernández M, Ríos-Villegas MJ, Márquez-Solero M, Merino D, Pasquau J, García-Figueras C, Martínez-Pérez MA, Omar M, Rivero A, Macías J, Mata R, Pineda JA; Grupo Andaluz para el Estudio de las Hepatitis Vıricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).

AIDS Patient Care STDS. 2011 Jul;25(7):395-402. doi: 10.1089/apc.2011.0109. Epub 2011 Jun 20.

PMID:
21688986
[PubMed - indexed for MEDLINE]
10.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
[PubMed - indexed for MEDLINE]
11.

Salvage therapy with ritonavir-boosted amprenavir/fosamprenavir: virological and immunological response in two years follow-up.

Quercia R, Garnier E, Ferré V, Morineau P, Bonnet B, Soulard C, Raffi F.

HIV Clin Trials. 2005 Mar-Apr;6(2):73-80.

PMID:
15983891
[PubMed - indexed for MEDLINE]
Free Article
12.

Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758.

Hicks CB, DeJesus E, Sloan LM, Sension MG, Wohl DA, Liao Q, Ross LL, Pakes GE, Pappa KA, Lancaster CT; COL100758 Study Team.

AIDS Res Hum Retroviruses. 2009 Apr;25(4):395-403. doi: 10.1089/aid.2008.0231.

PMID:
19320570
[PubMed - indexed for MEDLINE]
13.

Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.

Ross LL, Weinberg WG, DeJesus E, Fischl MA, Horton JH, Pappa KA, Lancaster CT, Pakes GE, Smith KY.

AIDS Res Hum Retroviruses. 2010 Apr;26(4):407-17. doi: 10.1089/aid.2009.0189.

PMID:
20380480
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population.

Rusconi S, Giacomet V, Mameli C, Viganò A, Viganò O, Adorni F, Galli M, Zuccotti GV.

BMC Infect Dis. 2012 Aug 6;12:179. doi: 10.1186/1471-2334-12-179.

PMID:
22866946
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.

Smith KY, Weinberg WG, Dejesus E, Fischl MA, Liao Q, Ross LL, Pakes GE, Pappa KA, Lancaster CT; ALERT (COL103952) Study Team.

AIDS Res Ther. 2008 Mar 28;5:5. doi: 10.1186/1742-6405-5-5.

PMID:
18373851
[PubMed]
Free PMC Article
16.

Hepatic safety profile of fosamprenavir-containing regimens in HIV-1-infected patients with or without hepatitis B or C coinfection.

Ha B, Wine B, Rodriguez-Alcantra F, Shaefer M.

HIV Clin Trials. 2012 May-Jun;13(3):171-7. doi: 10.1310/hct1303-171.

PMID:
22592097
[PubMed - indexed for MEDLINE]
17.

Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals.

Ramos JT, De José MI, Dueñas J, Fortuny C, González-Montero R, Mellado MJ, Mur A, Navarro M, Otero C, Pocheville I, Muñoz-Fernández MA, Cabrero E; Spanish Collaborative Group on HIV Infection in Children.

Pediatr Infect Dis J. 2005 Oct;24(10):867-73.

PMID:
16220083
[PubMed - indexed for MEDLINE]
18.

Height, weight, and growth in children born to mothers with HIV-1 infection in Europe.

Newell ML, Borja MC, Peckham C; European Collaborative Study.

Pediatrics. 2003 Jan;111(1):e52-60.

PMID:
12509595
[PubMed - indexed for MEDLINE]
19.

Fosamprenavir clinical study meta-analysis in ART-naïve subjects: rare occurrence of virologic failure and selection of protease-associated mutations.

Ross L, Vavro C, Wine B, Liao Q.

HIV Clin Trials. 2006 Nov-Dec;7(6):334-8.

PMID:
17197380
[PubMed - indexed for MEDLINE]
Free Article
20.

Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.

Pérez-Elias MJ, Sánchez-Conde M, Soriano V, Mallolas J, Luque I, Rodríguez-Alcántara F; Fosamprenavir Expanded Access Program Group.

Enferm Infecc Microbiol Clin. 2009 Jan;27(1):28-32. doi: 10.1016/j.eimc.2008.05.002. Epub 2009 Jan 9.

PMID:
19218000
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk